How to Make Drug Discovery Successful with In Vitro Toxicity Testing Methods?
Serious concerns about animal testing for drug discovery and testing have opened the way for the reduction or replacement of animal testing with an effective in vitro toxicity testing. What is In Vitro Toxicity Testing? Regulatory agencies around the globe are accepting in vitro data as a replacement for animal testing studies. To predict the toxic properties of compounds and mixtures, In Vitro Toxicity Testing uses cells or tissues maintained or grown in controlled laboratory conditions. With cost-effective as well as time saving benefits, In Vitro Toxicity Testing offers you a quick assessment about your drug safety. For these reasons, drug developers nowadays are more inclined towards In Vitro Toxicology screening of their drug.
The crucial part that plays a major role in drug safety profiles is – toxicity assessment. Yes, the assessment of your drug toxicity is the main reason for drug development termination and withdraw from the market. Thus, an early stage assessment of the toxicity level of your candidate drug is vital to save valuable time and cost. Nowadays, there are many fast, affordable and highly efficient In Vitro assays for assessing drug safety risks recommended by most regulatory authorities. Selecting a Contract Research Organization (CRO) to perform In Vitro Toxicity Testing In vitro toxicity testing assays bring a number of technical benefits to the traditional method of testing substances on animal models. These benefits include: the capacity to clear cellular-response networks and toxicity pathways; the utilization of concentrations relative to human exposure; and enabling high-throughput studies. So, choose worldclass In Vitro Toxicity Testing with a well-established CRO – IONTOX. IONTOX is highly specialized in vitro methods following both GCCP GIVIMP guidelines. IONTOX in vitro toxicity testing service includes cytotoxicity screens, organ specific toxicity assessments and 3D tissue models for OECD compliant irritation studies. To assess systemic toxicity, a meso-scale, human based, flexible HuDMOP platform is used. Cytotoxicity screening is done to predict compound viability early in the preclinical stage of drug development or new product discovery. Cytotoxicity screens range from multi-endpoint models to standard cell viability screens (ATP) to order compounds or mitochondrial toxicity predictions for companies wanting to comprehend how their compound affects mitochondrial health. All 3D testing-ocular irritation, dermal irritation and dermal corrosion assays are run in accordance with OECD Guidelines. To know how a compound may affect the health of a particular organ, organ specific toxicity testing is performed. Pharmaceutical, chemical, and cosmetic businesses who manufacture products for topical use not only have to ensure the safety of a product, but they are also often needed to do these safety studies without animal testing. Organ specific toxicity testing is highly predictive of the real effects of these products on human skin. For more information regarding innovative In Vitro Toxicity Testing, visit https://www.iontox.com/in-vitro-toxicity-testing/ now.